The Food and Drug Administration (FDA) considers aging to be a natural process. This makes it difficult to get FDA approval for drugs that seek to slow or reverse the biological process of aging. Instead, drugs intended to target aging must target a disease that often results from the aging process in order to demonstrate efficacy and gain approval. But there is growing consensus and effort among scientists to convince the FDA that aging itself should be classified as a disease and an appropriate target for drug development. This could be a major milestone for not just industry, but society. If the FDA is swayed, the resulting regulatory shift could mean approval of drugs or treatme
Hence then, the article about classifying aging as a disease could speed fda drug approvals was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Classifying aging as a disease could speed FDA drug approvals )